Provided by Tiger Trade Technology Pte. Ltd.

XORTX Therapeutics Inc.

1.71
-0.0158-0.91%
Post-market: 1.710.00000.00%19:00 EDT
Volume:4K
Turnover:7.76K
Market Cap:3.11M
PE:-0.61
High:1.79
Open:1.72
Low:1.70
Close:1.73
52wk High:7.05
52wk Low:1.59
Shares:1.82M
Float Shares:1.79M
Volume Ratio:0.11
T/O Rate:0.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8252
EPS(LYR):-2.8052
ROE:-99.24%
ROA:-29.85%
PB:0.57
PE(LYR):-0.61

Loading ...

Xortx Therapeutics announces planned FDA IND submission for XRx-026

TIPRANKS
·
Sep 18

XORTX Plans Q4 2026 FDA IND Filing for XRx-026 Gout Trial Using Xorlo, Targets USD 700 Million U.S. Market

Reuters
·
Sep 18

XORTX Therapeutics - to Submit Ind to FDA in Q4 2026

THOMSON REUTERS
·
Sep 18

XORTX Therapeutics - Announces Initiation of Drug and Tablet Manufacturing for Xrx-026 Program

THOMSON REUTERS
·
Sep 11

XORTX Starts GMP Manufacturing for XORLO to Support XRX-OXY-102 Gout Trial

Reuters
·
Sep 11

XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™

GlobeNewswire
·
Sep 11

XORTX Announces Termination and Postponement of Investor Relations Program

GlobeNewswire
·
Aug 28

XORTX Announces Director Resignation

GlobeNewswire
·
Aug 01

Press Release: XORTX Appoints New Director

Dow Jones
·
Jul 29

Xortx Therapeutics announces Mika Grasso as co-CEO

TIPRANKS
·
Jun 15

XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO

GlobeNewswire
·
Jun 15

XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange

GlobeNewswire
·
Jun 13

XORTX Announces Closing of US$5 Million Public Offering

GlobeNewswire
·
May 19

XORTX Therapeutics Inc expected to post a loss of C$1.64 a share - Earnings Preview

Reuters
·
May 16

Xortx Therapeutics 2.66M share Spot Secondary priced at $1.88

TIPRANKS
·
May 15

XORTX Announces US$5 Million Public Offering

GlobeNewswire
·
May 14

XORTX Therapeutics Inc expected to post a loss of C$1.64 a share - Earnings Preview

Reuters
·
May 12

Xortx Therapeutics meets Nasdaq continued listing requirements

TIPRANKS
·
Apr 21

XORTX Meets Nasdaq Continued Listing Requirements

GlobeNewswire
·
Apr 21

XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset

GlobeNewswire
·
Apr 14